Literature DB >> 3691661

One to three day dose intervals during subchronic treatment of epileptic gerbils with gamma-vinyl GABA: anticonvulsant efficacy and alterations in regional brain GABA levels.

W Löscher1, H H Frey.   

Abstract

gamma-Vinyl GABA (GVG), an irreversible inhibitor of GABA degradation, was administered to seizure-susceptible gerbils at different dosage regimens. After acute i.p. administration, GVG dose dependently protected the animals against air blast-induced seizures with an ED50 of 50 mg/kg. After oral administration, GVG exerted similar anticonvulsant potency. However, during subchronic daily oral dosing of 100 mg/kg GVG, tolerance developed to the anticonvulsant effect of the treatment. No tolerance was observed with daily oral dosing of 50 mg/kg or every other day and every third day dosing of 100 mg/kg GVG. The disadvantage of the two latter dosage regimens was that no sufficient seizure control was obtained on the days between two administrations. Determination of GABA levels in 11 brain regions of gerbils after subchronic treatment with the different dosage regimens of GVG indicated that tolerance during treatment with daily administration of 100 mg/kg GVG could be the consequence of feedback reduction of GABA synthesis. The data suggest that the choice of suitable dosage regimens for chronic treatment is more critical with GVG than with other antiepileptic drugs, because compensatory mechanisms within the GABA system may develop when GVG-induced GABA accumulation is too marked.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3691661     DOI: 10.1016/0014-2999(87)90457-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

Review 1.  Measuring human brain GABA in vivo: effects of GABA-transaminase inhibition with vigabatrin.

Authors:  O A Petroff; D L Rothman
Journal:  Mol Neurobiol       Date:  1998-02       Impact factor: 5.590

2.  Sub-chronic low dose gamma-vinyl GABA (vigabatrin) inhibits cocaine-induced increases in nucleus accumbens dopamine.

Authors:  Wynne K Schiffer; Douglas Marsteller; Stephen L Dewey
Journal:  Psychopharmacology (Berl)       Date:  2003-04-09       Impact factor: 4.530

Review 3.  Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control.

Authors:  S M Grant; R C Heel
Journal:  Drugs       Date:  1991-06       Impact factor: 9.546

Review 4.  Newer antiepileptic drugs. Towards an improved risk-benefit ratio.

Authors:  P N Patsalos; J W Sander
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

5.  Development of tolerance to the effects of vigabatrin (gamma-vinyl-GABA) on GABA release from rat cerebral cortex, spinal cord and retina.

Authors:  M J Neal; M A Shah
Journal:  Br J Pharmacol       Date:  1990-06       Impact factor: 8.739

6.  Subchronic treatment with antiepileptic drugs modifies pentylenetetrazol-induced seizures in mice: Its correlation with benzodiazepine receptor binding.

Authors:  Luisa Rocha
Journal:  Neuropsychiatr Dis Treat       Date:  2008-06       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.